Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

References

• RowleyJDLetter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa stainingNature197324354052902934126434
   PubMed Web of Science ®Google Scholar
• SattlerMScheijenBWeisbergEGriffinJDMutated tyrosine kinases as therapeutic targets in myeloid leukemiasAdv Exp Med Biol200353212114012908554
   PubMed Web of Science ®Google Scholar
• DeiningerMWO’BrienSGFordJMDrukerBJPractical management of patients with chronic myeloid leukemia receiving imatinibJ Clin Oncol20032181637164712668652
   PubMed Web of Science ®Google Scholar
• O’BrienSGGuilhotFGoldmanJMInternational randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM)Blood2008112 Abstr 186
   Web of Science ®Google Scholar
• SawyersCLHochhausAFeldmanEImatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II studyBlood200299103530353911986204
   PubMed Web of Science ®Google Scholar
• BuchdungerEZimmermannJMettHInhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivativeCancer Res19965611001048548747
   PubMed Web of Science ®Google Scholar
• DeiningerMO’BrienSGGuilhotFInternational randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinibBlood2009114 Abstr 1126
   Web of Science ®Google Scholar
• de LavalladeHApperleyJFKhorashadJSImatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysisJ Clin Oncol200826203358336318519952
   PubMed Web of Science ®Google Scholar
• ErnstTHochhausAChronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progressionSemin Oncol2012391586622289492
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFWunderleLNilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med2006354242542255116775235
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood200710962303230917138817
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHMBrummendorfTHSafety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood2011118174567457621865346
   PubMed Web of Science ®Google Scholar
• SaglioGKimDWIssaragrisilSNilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med2010362242251225920525993
   PubMed Web of Science ®Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2010362242260227020525995
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWKantarjianHMBosutinib versus imatinib in newly diagnosed chronic – phase chronic myeloid leukemia, Results from the BELA trailJ Clin Oncol201230283486349222949154
   PubMed Web of Science ®Google Scholar
• LevinsonNMBoxerSGStructural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domainPLoS One201274e2982822493660
   PubMed Web of Science ®Google Scholar
• ThomasSMBruggeJSCellular functions regulated by Src family kinasesAnnu Rev Cell Dev Biol1997135136099442882
   PubMed Web of Science ®Google Scholar
• SummyJMGallickGESrc family kinases in tumor progression and metastasisCancer Metastasis Rev200322433735812884910
   PubMed Web of Science ®Google Scholar
• JohnsonFMGallickGESRC family nonreceptor tyrosine kinases as molecular targets for cancer therapyAnticancer Agents Med Chem20077665165918045060
   PubMed Web of Science ®Google Scholar
• LiSSrc-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemiaLeuk Lymphoma2008491192618203007
   PubMed Web of Science ®Google Scholar
• BoschelliDHYeFWangYDOptimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activityJ Med Chem200144233965397711689083
   PubMed Web of Science ®Google Scholar
• LaneuvillePAbl tyrosine protein kinaseSemin Immunol1995742552668520030
   PubMedGoogle Scholar
• PendergastAMNuclear tyrosine kinases: from Abl to WEE1Curr Opin Cell Biol1996821741818791414
   PubMed Web of Science ®Google Scholar
• ChungSWDanielRWongBYWongPMThe ABL genes in normal and abnormal cell developmentCrit Rev Oncog199671–233489109496
   PubMed Web of Science ®Google Scholar
• GolasJMArndtKEtienneCSKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude miceCancer Res200363237538112543790
   PubMed Web of Science ®Google Scholar
• Remsing RixLLRixUColingeJGlobal target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cellsLeukemia200923347748519039322
   PubMed Web of Science ®Google Scholar
• ManciniMBrusaGZuffaEPersistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606Leuk Res200731797998717129604
   PubMed Web of Science ®Google Scholar
• PuttiniMColucciaAMBoschelliFIn vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cellsCancer Res20066623113141132217114238
   PubMed Web of Science ®Google Scholar
• KhouryHJCortesJEKantarjianHMBosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood2012119153403341222371878
   PubMed Web of Science ®Google Scholar
• AbbasRHugBALeisterCGaaloulMEChalonSSonnichsenDA phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjectsCancer Chemother Pharmacol201269122122721691746
   PubMed Web of Science ®Google Scholar
• GontarewiczABalabanovSKellerGSimultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315IBlood200811184355436418268096
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaACortesJHomoharringtonine for the treatment of chronic myelogenous leukemiaExpert Opin Pharmacother2008961029103718377344
   PubMed Web of Science ®Google Scholar
• CortesJEKimD-WPinilla-IbarzJThe PACE Study GroupInitial findings from the PACE trial: a pivotal Phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutationBlood2011118 Abstr 109
   Web of Science ®Google Scholar
• O’HareTEideCADeiningerMWNew Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in checkExpert Opin Investig Drugs2008176865878
   PubMed Web of Science ®Google Scholar
• CortesJTalpazMBixbyDA Phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findingsBlood2010116 Abstr 210
   Web of Science ®Google Scholar
• LarsonRAHochhausAHughesTPNilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLeukemia201226102197220322699418
   PubMed Web of Science ®Google Scholar
• HuYLiuYPelletierSRequirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemiaNat Genet200436545346115098032
   PubMed Web of Science ®Google Scholar
• HuYSwerdlowSDuffyTMWeinmannRLeeFYLiSTargeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in miceProc Natl Acad Sci U S A200610345168701687517077147
   PubMed Web of Science ®Google Scholar
• PtasznikANakataYKalotaAEmersonSGGewirtzAMShort interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cellsNat Med200410111187118915502840
   PubMed Web of Science ®Google Scholar
• BantscheffMEberhardDAbrahamYQuantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNat Biotechnol20072591035104417721511
   PubMed Web of Science ®Google Scholar
• Keller-vAmsbergGBrümmendorfTHNovel aspects of therapy with the dual Src and Abl Kinase inhibitor bosutinib in chronic myeloid leukemiaExpert Rev Anticancer Ther20121291121112723098112
   PubMed Web of Science ®Google Scholar
• KonigHHolyoakeTLBhatiaREffective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606Blood200811142329233818056843
   PubMed Web of Science ®Google Scholar
• BartolovicKBalabanovSHartmannUInhibitory effect of imatinib on normal progenitor cells in vitroBlood2004103252352912969987
   PubMed Web of Science ®Google Scholar
• BraveMGoodmanVKaminskasESprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylateClin Cancer Res200814235235918223208
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAHanXKantarjianHCortesJTyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemiaBlood2009114226126319414863
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantarjianHDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med2006354242531254116775234
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHO’BrienSPleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failureJ Clin Oncol200725253908391417761974
   PubMed Web of Science ®Google Scholar
• Gora-TyborJRobakTTargeted drugs in chronic myeloid leukemiaCurr Med Chem200815293036305119075651
   PubMed Web of Science ®Google Scholar
• MustjokiSEkblomMArstilaTPClonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapyLeukemia20092381398140519295545
   PubMed Web of Science ®Google Scholar
• LimaLBernal-MizrachiLSaxeDPeripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyondCancer201111761245125221381013
   PubMed Web of Science ®Google Scholar
• MarinDIbrahimARLucasCAssessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsJ Clin Oncol201230323223822067393
   PubMed Web of Science ®Google Scholar
• HanfsteinBMullerMCHehlmannREarly molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Leukemia20122692096210222446502
   PubMed Web of Science ®Google Scholar
• CoplandMHamiltonAElrickLJDasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionBlood2006107114532453916469872
   PubMed Web of Science ®Google Scholar
• HelgasonGVKarvelaMHolyoakeTLKill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CMLBlood201111882035204321693757
   PubMed Web of Science ®Google Scholar
• RedaelliSPiazzaRRostagnoRActivity of bosutinib, dasatinib, and nilotinib against 18 imatinib resistant BCR/ABL mutantsJ Clin Oncol200927346947119075254
   PubMed Web of Science ®Google Scholar